These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

Benzinga

07 May

CRISPR Therapeutics AG (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.

The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.

“CRISPR Therapeutics remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”

CRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.

These analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.

Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.
Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.

Considering buying CRSP stock? Here’s what analysts think:

Read This Next:

Top 2 Energy Stocks That Are Ticking Portfolio Bombs

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2533987747"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533987747\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2533987747?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533987747","market":"hk","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/CRSP\">CRISPR Therapeutics AG</a></strong> (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.</p>\n<p>“CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”</p>\n<p>CRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.</p>\n<p>These analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.</p>\n<ul>\n<li>Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.</li>\n<li>Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.</li>\n</ul>\n<p><strong>Considering buying CRSP stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"619\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26.png 1095w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Energy Stocks That Are Ticking Portfolio Bombs</strong> </li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-05-07 20:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/CRSP\">CRISPR Therapeutics AG</a></strong> (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.</p>\n<p>“CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”</p>\n<p>CRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.</p>\n<p>These analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.</p>\n<ul>\n<li>Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.</li>\n<li>Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.</li>\n</ul>\n<p><strong>Considering buying CRSP stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"619\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26.png 1095w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Energy Stocks That Are Ticking Portfolio Bombs</strong> </li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/25/05/45250973/these-analysts-slash-their-forecasts-on-crispr-therapeutics-following-q1-results","article_id":"2533987747","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533987747","pubTimestamp":1746621581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","BK4588":"碎股","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","LENZ":"Therapeutics","LU1861558580.USD":"日兴方舟颠覆性创新基金B","CRSP":"CRISPR Therapeutics AG","BK4611":"AI医疗"},"translate_title":"这些分析师在第一季度业绩公布后大幅下调了对CRISPR Therapeutics的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1,"LENZ":1},"content_text":"CRISPR Therapeutics AG (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.\nThe company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.\n“CRISPR Therapeutics remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”\nCRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.\nThese analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.\n\nChardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.\nNeedham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.\n\nConsidering buying CRSP stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 2 Energy Stocks That Are Ticking Portfolio Bombs \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}